Skip to content

Author

Magdi E. A. Zaki

We have 8 of 27 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Exploring the Anticancer Potential of Plant, Marine, and Synthetic Glycosides: A Comprehensive Review

Despite advances in pharmaceutical and technological development, cancer continues to be a life-threatening illness globally. In addition to other specialized procedures, radiotherapy, chemotherapy, and surgery are methods used to treat cancer. However, in recent years, natural products have either been used as food su...

Tooba Jabeen, S. Akram, Matloob Ahmad et al. · 0 citations
Oct 2026

Interrogating imidazo[2,1-b]thiazole-4-thiazolidinone hybrids as antidiabetic leads: molecular cartography, pharmacokinetic profiling and rodent therapeutic response.

Diabetes mellitus remains a major global health challenge, necessitating the development of new therapeutic agents targeting key enzymes involved in carbohydrate metabolism. In this study, ten novel imidazo-thiazole-thiazolidinone hybrids were designed, synthesized and their structural integrity was confirmed through 1...

S. Bano, Shoaib Khan, Sampath Chinnam et al. · 0 citations
Open access Oct 2026

Synthesis, antitumor evaluation, and in silico investigation of pyridine-based pyrimidotriazine and triazolopyrimidine derivatives as potential EGFR-targeted anticancer agents

Cancer remains a major global health challenge and one of the leading causes of mortality worldwide. In the present study, a new series of fused nitrogen-containing heterocyclic derivatives was synthesized from a pyridine-based pyrimidinethione key synthon. Hydrazinolysis followed by cyclo-condensation and condensation...

S. K. Ramadan, Ali H. Abdelrahman, M. Hegazy et al. · 0 citations
Open access Oct 2026

Strategic development of benzimidazole-derived glycosidase modulators for antihyperglycemic intervention: a comprehensive medicinal study integrating molecular docking, biological evaluation, in vivo validation and pharmacokinetic assessment.

Current in silico drug discovery workflows largely rely on ligand-based screening and structure-based molecular docking to identify enzyme inhibitors, often overlooking dynamic biological contexts that influence drug efficacy and stability. Integrating multiscale computational modeling with experimental validation at e...

Zanib Fiaz, Shoaib Khan, Tayyiaba Iqbal et al. · 0 citations
Open access Sep 2026

Quinazoline-tethered thiazolo[3,2-a]pyrimidines and their cyclic chalcone derivatives as HIV-1 reverse transcriptase inhibitors: green synthesis, molecular docking, and in silico studies

Nitrogen-fused heterocycles have attracted considerable research interest in pharmaceutical, medicinal, organometallic, and materials chemistry. In this work, two new series of quinazoline-linked thiazolo[3,2-a]pyrimidines and their cyclic chalcone derivatives were synthesized using choline hydroxide as an environmenta...

S. M. Gomha, Sami A. Alhussain, Yaser A. M. Sulaiman et al. · 0 citations
Open access Sep 2026

Quinazolinone–diarylpyrazole hybrids as dual EGFR/COX-2 inhibitors: antiproliferative, mechanistic, and in silico studies

7f is identified as a promising lead displaying concurrent EGFR and COX-2 inhibitory activity together with pronounced antiproliferative effects, consistent with its experimentally observed dual inhibitory activity.

Abdullah Alkhammash, B. A. Saleem, Khulood H. Oudah et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.